This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
Should You Buy Phillips 66 (PSX) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PSXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy OMV AG (OMVJF) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OMVJFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Midland States Bancorp (MSBI) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MSBIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
The Stock-Picking Puzzle: Putting The Pieces Together
by Bryan Hayes
The Stock-Picking Puzzle: Putting The Pieces Together
ABCPositive Net Change MCKPositive Net Change HSICNegative Net Change
coronavirus dental dividend-investing dividends earnings hospitals investing large-cap medical medical-devices oncology-screening pharmaceuticals smart-health staffing vaccines
Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH
by Sundeep Ganoria
Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.
PFEPositive Net Change MRKNegative Net Change INCYPositive Net Change DCPHPositive Net Change
biotechs medical pharmaceuticals vaccines
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
Groundhog Sees -301K Private-Sector Jobs from ADP
by Mark Vickery
This was the first negative number on ADP headline since December 2020, and the biggest monthly loss since April 2020.
ADPNegative Net Change QQQPositive Net Change SPYPositive Net Change DIAPositive Net Change
staffing vaccines
After Golden Cross, Tenaris S.A. (TS)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical vaccines
After Golden Cross, NexTier Oilfield Solutions (NEX)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
RPC (RES)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
RESPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.
PFEPositive Net Change ALKSPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs medical messenger-rna vaccines
After Golden Cross, Atlantic Union (AUB)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AUBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant
by Zacks Equity Research
Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.
AZNNegative Net Change PFEPositive Net Change MRNAPositive Net Change VALNNegative Net Change
medical vaccines
AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron
by Zacks Equity Research
Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.
AZNNegative Net Change PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
medical messenger-rna pharmaceuticals vaccines
Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study
by Zacks Equity Research
Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.
ALKSPositive Net Change VIRPositive Net Change BNTXNegative Net Change VAXXNegative Net Change
biotechs medical vaccines
Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds
by Zacks Equity Research
Pfizer's (PFE) data from a phase III study showed that its COVID-19 vaccine and pneumococcal conjugate vaccine, Prevnar-20 can be given at the same time.
REGNNegative Net Change PFEPositive Net Change ABBVNegative Net Change BNTXNegative Net Change
pharmaceuticals vaccines
Can U.S. Healthcare Handle Another Peak COVID Surge?
by John Blank
What of the performance of the U.S. healthcare system, during such a mammoth COVID caseload and hospitalization crisis?
QQQPositive Net Change SPYPositive Net Change DIAPositive Net Change
hospitals medical vaccines
HollyFrontier (HFC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
HFCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Titan International (TWI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
TWIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sabre (SABR) Adds Travel Restriction Tracking in SafePoint
by Zacks Equity Research
Sabre (SABR) expands its travel risk management solutions portfolio, SafePoint, by adding global travel restriction tracking capability and ensuring increased traveler safety.
AMDPositive Net Change CRMPositive Net Change SABRPositive Net Change HPEPositive Net Change
computers tech-stocks travel-leisure vaccines
AAR (AIR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AIRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Winnebago Industries (WGO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
WGOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
pharmaceuticals vaccines
Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
pharmaceuticals vaccines